NeuroPace falls after epilepsy implant fails to meet main study goal

Shares of medical device maker NeuroPace NPCE.O fall 15% to $15.02 premarket

Co, citing preliminary data, says neuromodulation therapy for a group of genetic epilepsy syndromes failed to meet main efficacy goal in the overall population in a 2-year study

The device, RNS System, is implanted in the skull to constantly monitor brain waves, identifying and disrupting unusual activity that may trigger seizures

The device, however, showed significant efficacy in a subset of patients, which represents the majority of participants - NPCE

It is approved in the U.S. to treat focal epilepsy, a type of seizure that affects only one side of the brain and body

Up to last close, stock up ~58% YTD